Shattuck Labs, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 5.72 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 574.08M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical DR3-based bispecific antibodies for the treatment of patients with inflammatory bowel disease or other immune-mediated indications; and TRIM7, an oncology-focused program. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Details
| Name | Shattuck Labs, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 40 |
| Founded | 2016 |
| Ipo Date | 2020-10-09 |
| Ceo | Taylor Schreiber |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 17.00 |
| Isin | US82024L1035 |
| Cusip | 82024L103 |
| Cik | 1680367 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Taylor H. Schreiber M.D., Ph.D. | Co-Founder, Chief Executive Officer and Director |
| Andrew R. Neill M.B.A. | Chief Financial Officer |
| Dr. Arunthathy Nirmalini Pandite M.B.A., M.D. | Chief Medical Officer |
| Brad Huckabee | Vice President of Accounting and SEC reporting |
| Dr. Abhinav A. Shukla Ph.D. | Chief Technical Officer |
| Suresh de Silva Ph.D. | Chief Scientific Officer |
| Dr. Stephen Stout J.D., Ph.D. | General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer |
| Casi DeYoung | Chief Business Officer |
| Dr. Thomas Lampkin Pharm.D. | Senior Vice President of Regulatory Affairs |
| Kelli Collin M.B.A., M.S. | Senior Vice President of Quality |
Contact
| Address | 500 West 5th Street, Suite 1200, Austin, Texas 78701, United States |
| Phone | 512 900 4690 |
| Website | https://www.shattucklabs.com |